Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL696377 | 0.98 | L3MBTL1 (0.43) | L3MBTL1LMNAKMT2AHPGDEPHX1 | |
| SCHEMBL697749 | 0.94 | L3MBTL1 (0.43) | L3MBTL1LMNAKMT2AHPGDEPHX1 | |
| SCHEMBL697321 | 0.89 | — | — | |
| SCHEMBL1439009 | 0.84 | L3MBTL1 (0.41) | L3MBTL1LMNAKMT2AHPGDEPHX1 | |
| SCHEMBL5569311 | 0.82 | L3MBTL1 (0.41) | L3MBTL1LMNAKMT2AHPGDEPHX1 | |
| SCHEMBL4005674 | 0.80 | MAPT (0.50) | L3MBTL1LMNAKMT2AHPGDALDH1A1 | |
| SCHEMBL25311355 | 0.79 | TDP1 (0.50) | L3MBTL1LMNAKMT2AHPGDEPHX1 | |
| SCHEMBL9134377 | 0.79 | TDP1 (0.50) | L3MBTL1LMNAKMT2AHPGDEPHX1 | |
| SCHEMBL1784329 | 0.79 | L3MBTL1 (0.47) | L3MBTL1LMNAKMT2AHPGDEPHX1 | |
| SCHEMBL18797 | 0.79 | TDP1 (0.50) | L3MBTL1LMNAKMT2AHPGDEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007096740-A2 | NOVEL CEPHALOSPORINS | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2007-08-30 | — | — | WO | claimed |
| US-5597943-A | Phospholipase A2 inhibitor | SHIONOGI & CO., LTD. (JP) | 1997-01-28 | — | — | US | claimed |
| EP-0643059-A1 | 3-(3-Pyridinyl)-1H-indoles as thromboxane A2 synthetase inhibitors | Pfizer Limited (GB) | 1995-03-15 | — | — | EP | claimed |
| EP-0594588-A1 | CYCLOALKYL-SUBSTITUTED GLUTARAMIDE ANTIHYPERTENSIVE AGENTS | Pfizer Limited (GB) | 1994-05-04 | — | — | EP | claimed |
| US-5268386-A | Containing a carboxy group | SHIONOGI & CO., LTD. (JP) | 1993-12-07 | — | — | US | claimed |
| EP-0358398-B1 | CYCLOALKYL-SUBSTITUTED GLUTARAMIDE ANTIHYPERTENSIVE AGENTS | Pfizer Limited (GB) | 1993-03-10 | — | — | EP | claimed |
| WO-1991013054-A1 | CYCLOALKYL-SUBSTITUTED GLUTARAMIDE ANTIHYPERTENSIVE AGENTS | PFIZER LIMITED (GB) | 1991-09-05 | — | — | WO | claimed |
| EP-0358398-A1 | Cycloalkyl-substituted glutaramide antihypertensive agents | Pfizer Limited (GB) | 1990-03-14 | — | — | EP | claimed |
| US-9937157-B2 | Modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors | TAKEDA PHARMACEUTICALS U.S.A., INC. (US) | 2018-04-10 | — | — | US | disclosed |
| EP-2582812-B1 | NOVEL MODIFIED RELEASE DOSAGE FORMS OF XANTHINE OXIDOREDUCTASE INHIBITOR OR XANTHINE OXIDASE INHIBITORS | TAKEDA PHARMACEUTICALS USA INC (US) | 2018-01-24 | — | — | EP | disclosed |
| US-20160317505-A1 | NOVEL MODIFIED RELEASE DOSAGE FORMS OF XANTHINE OXIDOREDUCTASE INHIBITOR OR XANTHINE OXIDASE INHIBITORS | TAKEDA PHARMACEUTICALS U.S.A., INC. (US) | 2016-11-03 | — | — | US | disclosed |
| US-9248119-B2 | Modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors | TAKEDA PHARMACEUTICALS U.S.A., INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-9107912-B2 | Methods for concomitant treatment of theophylline and febuxostat | TAKEDA PHARMACEUTICALS U.S.A., INC. (US) | 2015-08-18 | — | — | US | disclosed |
| EP-2613780-B1 | METHODS FOR CONCOMITANT TREATMENT OF THEOPHYLLINE AND FEBUXOSTAT | TAKEDA PHARMACEUTICALS USA INC (US) | 2014-11-12 | — | — | EP | disclosed |
| US-4975444-A | INHIBITORS OF ANGIORENSIN-CONVERTING ENZYME AS WELL AS A ENDOPEPTIDASE; CARDIOTONIC AGENTS; GLAUCOMA; DIURETICS | PFIZER INC. (US) | 1990-12-04 | — | — | US | disclosed |
| EP-0384747-A1 | Pharmaceutical or veterinary preparations of substituted hexenoic acid derivatives | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1990-08-29 | — | — | EP | disclosed |
| EP-0358398-A1 | Cycloalkyl-substituted glutaramide antihypertensive agents | Pfizer Limited (GB) | 1990-03-14 | — | — | EP | disclosed |
| EP-0348203-A1 | Phenolic thioethers, their production and use | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1989-12-27 | — | — | EP | disclosed |
| US-4731362-A | Alkylcarbamoyloxymethylcephem compounds | SHIONOGI & CO., LTD. (JP) | 1988-03-15 | — | — | US | disclosed |
| US-4731361-A | Alkeneamidocephalosporin esters | SHIONOGI & CO., LTD. (JP) | 1988-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160317505-A1 | NOVEL MODIFIED RELEASE DOSAGE FORMS OF XANTHINE OXIDOREDUCTASE INHIBITOR OR XANTHINE OXIDASE INHIBITORS | XDH, PNPO, DUOX1 | L3MBTL1 4216/4885LMNA 3431/4885KMT2A 3734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.